Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23525156 | 1.00 | CA12 (0.42) | CA12CA9GAAPOLBMAPT | |
| SCHEMBL28669122 | 0.98 | CA12 (0.41) | CA12CA9GAAPOLBMAPT | |
| SCHEMBL344919 | 0.82 | MME (0.45) | CA12CA9GAAPOLBMAPT | |
| SCHEMBL3488827 | 0.82 | MME (0.45) | CA12CA9GAAPOLBMAPT | |
| SCHEMBL344918 | 0.82 | MME (0.45) | CA12CA9GAAPOLBMAPT | |
| Water SCHEMBL4595531 | 0.80 | MME (0.44) | CA12CA9GAAPOLBMAPT | |
| Ammonia Solution, Strong SCHEMBL3276907 | 0.80 | MME (0.44) | CA12CA9GAAPOLBMAPT | |
| SCHEMBL3385432 | 0.80 | FNTA (0.44) | CA12CA9GAAPOLBMAPT | |
| Methane SCHEMBL9693759 | 0.80 | MME (0.44) | CA12CA9GAAPOLBMAPT | |
| SCHEMBL4526295 | 0.80 | ALDH1A1 (0.50) | CA12CA9GAAPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025006976-A2 | MRNA DISPLAY LIBRARIES AND METHODS OF USE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2025-01-02 | — | — | WO | claimed |
| CN-113749275-B | Electronic cigarette atomized liquid containing organic selenium compound | 张家港外星人新材料科技有限公司 | 2024-02-06 | — | — | CN | claimed |
| EP-1994165-B1 | Genetically programmed expression of proteins containing the unnatural amino acid phenylselenocysteine | SCRIPPS RESEARCH INST (US) | 2014-11-05 | — | — | EP | claimed |
| US-8394605-B2 | Genetically programmed expression of proteins containing the unnatural amino acid phenylselenocysteine | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-03-12 | — | — | US | claimed |
| US-20120282668-A1 | Genetically Programmed Expression of Proteins Containing the Unnatural Amino Acid Phenylselenocysteine | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-11-08 | — | — | US | claimed |
| US-8217145-B2 | Genetically programmed expression of proteins containing the unnatural amino acid phenylselenocysteine | THE SCRIPS RESEARCH INSTITUTE (US) | 2012-07-10 | — | — | US | claimed |
| US-7790847-B2 | Genetically programmed expression of proteins containing the unnatural amino acid phenylselenocysteine | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-09-07 | — | — | US | claimed |
| US-20090209000-A1 | Genetically Programmed Expression of Proteins | THE SCRIPPS RESEARCH INSTITUTE | 2009-08-20 | — | — | US | claimed |
| EP-1994165-A2 | GENETICALLY PROGRAMMED EXPRESSION OF PROTEINS CONTAINING THE UNNATURAL AMINO ACID PHENYLSELENOCYSTEINE | The Scripps Research Institute (US) | 2008-11-26 | — | — | EP | claimed |
| US-20070238152-A1 | Genetically programmed expression of proteins containing the unnatural amino acid phenylselenocysteine | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-10-11 | — | — | US | claimed |
| WO-2007109035-A2 | GENETICALLY PROGRAMMED EXPRESSION OF PROTEINS CONTAINING THE UNNATURAL AMINO ACID PHENYLSELENOCYSTEINE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-09-27 | — | — | WO | claimed |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2026-05-21 | — | — | US | disclosed |
| CN-122036912-A | Cytokine conjugates for the treatment of proliferative and infectious diseases | 辛索克斯公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260115295-A1 | IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND ANTI-EGFR ANTIBODIES | Synthorx, Inc. (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4725953-A1 | SELF-ASSEMBLING PEPTIDES AND HYDROGELS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-04-15 | — | — | EP | disclosed |
| US-20070238152-A1 | Genetically programmed expression of proteins containing the unnatural amino acid phenylselenocysteine | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-10-11 | — | — | US | disclosed |
| US-20070238152-A1 | Genetically programmed expression of proteins containing the unnatural amino acid phenylselenocysteine | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-10-11 | — | — | US | disclosed |
| WO-2007109035-A2 | GENETICALLY PROGRAMMED EXPRESSION OF PROTEINS CONTAINING THE UNNATURAL AMINO ACID PHENYLSELENOCYSTEINE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109035-A2 | GENETICALLY PROGRAMMED EXPRESSION OF PROTEINS CONTAINING THE UNNATURAL AMINO ACID PHENYLSELENOCYSTEINE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-09-27 | — | — | WO | disclosed |
| US-6579705-B2 | Generating preferential amino acid sequences; obtain adjusted amino acid, incubate with enzyme, recover amino acid | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) | 2003-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238152-A1 | Genetically programmed expression of proteins containing the unnatural amino acid phenylselenocysteine | NPEPPS, AARS1, NSUN3 | CA12 4769/4885CA9 4557/4885GAA 1686/4885 |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | STXBP1, HBB, UPF1 | CA12 4676/4885CA9 4794/4885GAA 3170/4885 |
| US-20090209000-A1 | Genetically Programmed Expression of Proteins | AARS1, COASY, NPEPPS | CA12 4737/4885CA9 4541/4885GAA 1770/4885 |
| US-20260115295-A1 | IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND ANTI-EGFR ANTIBODIES | IL2, IL2RA, EGFR | CA12 850/4885CA9 2126/4885GAA 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.